The term consumption-coagulopathy (CC) describes the hemostatic defect encountered in clinical syndromes of dis-eminated intravascular coagulation (DIC).
The basic event in CC and DIC is the intravascular activation of the coagulation system. This occurs as secondary complication in a number of diseases, which are known to involve the hemostatic system by one or more particular pathomechanisms.
Within my presentation I would like to summarize some clinical and diagnostic aspects of DIC, which have been of particular interest recently.
I shall refer mainly to two clinical entities with regard to the acute and chronic development of DIC:
1. to shock, and 2. to chirrhosis of the liver as models of acute and chronic hemostatic defects due to consumption-coagulopathy.
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First of all CC requires a more specific difinition:
it is characterized by three pathophysiological events:
1. procoagulant stimulation, which arises intravascularly and produces hypercoagulability, 2. concommittant deposition of microthrombi within the microcirculation and 3. defective hemostasis, due to an increased turn over to the hemostatic po-tential, particularly of fibrinogen, plasma factors and platelets. This process may be self-limited if the compensating mechanisms active against intravascular coagulation are intact.
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These are:
1. the inhibitors of coagulation represented particularly by antithrombin III, 2. the activation of the fibrinolytic system, and 3. the clearance of activated endproducts of coagulation and fibrinolysis, such as thromboplastins, soluble fibrins and activators, by the RES. The RES function depends on the phagocytotic capacity as well as on the adequate perfusion of the RES. 50% of its total capacity is represented by the Kupffer-cells of the liver.
Failure of these compensating principles will consequently promote irreversible generalized microthrombosis. The important role of hemodynamic failure as contributing factor to the depression of RES capacity by decrease of circulatory clearance is evident.
The involvement of secondary fibrinolysis might be itself an indicator of DIC.
It is caused by Slide 3 1. release of endothelial activator from vascular endothelium particularly from small veins, 2. the activator induces local lysis of microthrombi by local activation of coprecipitated plasminogen to plasmin, 3. following restitution of microcirculation fibrinolytic activators may invade systemic circulation promoting proteolytic degradation of circulating fibrinogen and further increased turn-over of the hemostatic potential. This attributes to severe hypocoagulability already induced by CC and may be followed at the endphase by the defibrination syndrome.
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With regard to the two decisive pathomechanisms operative in DIC-depletion The simplist way to demonstrate qualitatively the presence of soluble fibrin in plasma is the ethanol gelation test. It is, however, false negative in presence of fibrinolysis and hypofibrinogenemia and false positive in hyperfibrinogenemia.
Thus the interpretation of this test may be difficult.
Slide 17 (spared)
Gel filtration of plasma samples or plasma fractions according to FLETCHER as modified by GRAEFF separates high molecular weight fibrinogen derivatives from fibrinogen, as demonstrated by the shaded area, which can be quantitatively estimated by planimetry.
The specificity of this procedure is proven by means of disc electrophoretic analysis.
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Furthermore fibrinmonomer may be selectively adsorbed from plasma on to insolubilized fibrinogen using fibrinogen-agarose columns for affinity-chromatography. Following desorption fibrinmonomer is accessible to quantitative determination. The principle of this method is based on the complex forming properties of fibrinmonomer with fibrinogen.
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The next graph demonstrates the relationship of negative and positive ethanol tests to quantitative determination of fibrinmonomer by affinity-chromatography in patients with DIC. This graph showes that:
1. positive ethanol tests could be expected at fibrinmonomer levels above 7 mg/100 ml 2. negative ethanol tests do not exclude the presence of increased levels of fibrinmonomer.
The amount of fibrinmonomer usually correlated to the severity of CC involved in these cases.
Slide 20 (spared) Q uantitation of fibrinogen/fibrin degradation products (FDP) is achieved more Slide 21 This graph demonstrates the mortality of patients with shock indicated by the lower parts of the column for the different forms of shock. The incidence of hemorrhagic complications due to defective hemostasis is shown by the black parts of the columns. In cardiogenic shock and septic shock, which had mortality rates up to 80%, hemorrhagic complication weres negligeble. In traumatic shock and other forms, however, hemorrhagic complications were more frequently observed in the groups of survivors.
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The next slide shows the results of the analysis of fibrinogen derivatives as determined by means of the described methods in the same patients, indicating fibrinmonomer in the upper and FDP in the lower part of the graph. There is a high incidence of positive FDP tests in the shock groups with high incidence of hemorrhage and high survival rate. On the other hand, high levels of fibrinmonomer are more frequently associated with shock forms revealing high mortality rates and inadequate fibrinolytic response.
In conclusion it can be confirmed that:
1. activation of secondary fibrinolysis following shock is an important determinant of prognosis, 2. hemorrhagic complications in shock must not necessarily be a sign of doubtful prognosis as its cause can be attributed to secondary fibrinolysis.
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The factors operative in the interrelationship between shock and DIC are summarized in this graph. Shock and DIC may perpetuate themselves by CC and impairment of microciruclation. The involvement of hemorrhage seems more likely to be due to fibrinolysis than to CC. Bleeding, however, might, aggravate shock.
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The essential pathogenetic factors operating as trigger mechanisms in shock Slide 32 Consumption-coagulopathy in livercirrhosis 10: 333 2. production of abnormal, easily degraded fibrinogen 3. disproportional distribution of fibrinogen pool due to dilution or extravasation into the "third space" i.e. ascites in presence of portal hypertension.
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In addition, there are further arguments against the involvement of DIC in cirrhosis which are based on the observation that: What is now the present status of therapy of DIC?
In conclusion, there is general agreement that the treatment of the underlying disease is the essential therapeutic approach in order to prevent DIC. In acute CC the challenger or trigger mechnism of procoagulant stimulation has to be elimated. Heparin may be used either prophylactically or in therapeutic dosis if the increased turn over of hemostatic components has definately been verified by means of specific analytical procedures, and there are no contraindications concerning hemorrhage. The hemostatic defect otherwhise hat to bei treated by means of adequate substitution therapy with blood and plasma fractions. The use of natural inhibitors such as antithrombin III probably will be of advantage in the future.
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Clinical experience has shown, that heparin is in effective in the following conditions associated with DIC: septicemia, septic shock, purpura fulminans, hemolytic uremic syndrome, hyaline membrane disease abruption placentae and graft ref ection.
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In conclusion it has to be pointed put that all measures should be avoided, which, possibly may detonate on or more of the compensating mechanisms. Irreversibility of DIC only can be prevented by the availability and functioning of inhibitor potential, secondary fibrinolysis and the clearance capacity of the RES in presence of adequate circulation and intact hemodynamic function within the microcirculation.
